People who know, think Evolut First.
CoreValve™/Evolut™ is the first and only platform to outperform surgery in valve durability at five years.1
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The CoreValve™/Evolut™ TAVR system is the only TAVR platform to demonstrate a lower rate of SVD compared to SAVR at five years.
4.38% Surgery RCT (N = 971)
2.20% CoreValve™/Evolut™ RCT (N = 1,128)
Devices used:
88.5% CoreValve™ TAV
11.5% Evolut™ R
5-year SVD adjusted for competing risk of mortality†1
Medtronic TAVR platforms demonstrated significantly lower rates of structural valve deterioration (SVD)‡ vs. SAVR at five years.
TAVR risks may include, but are not limited to: death, stroke, damage to the arteries, bleeding, and the need for a permanent pacemaker.
Valve durability for supra-annular, self-expandable TAV was found to be statistically better at five years vs. both SAVR and balloon-expandable TAV.
At five years, supra-annular, self-expandable (SE) valves demonstrated:
Study design
Structural valve deteriorationll
Only SE performs better than SAVR.
Comparison: others versus SAVR
(random effects model)
SE performs better than SAVR and BE.
Comparison: others versus self-expandable
(random effects model)
Data show longevity after SAVR based on stratification by age and surgical risk groups.
With its supra-annular, self-expanding valve frame, Evolut™ TAVR is built on the original CoreValve™ platform, which has consistently shown strong EOAs and low gradients over time.
More surface
Taller leaflet mounting allows for a greater distance between the commissure and the edge of the leaflet, distributing stress over a greater distance.
More height
By decoupling the native annular plane, where the sealing occurs, from the working portion of the prosthetic leaflets, you can facilitate circularity and maximize leaflet coaptation.
More room
The tall valve keeps the working portion above and unconstrained by the native annulus, allowing for a large effective orifice area.
™Third-party brands are trademarks of their respective owners.
In pooled analysis of intermediate- and high-risk patients. Devices used: CoreValve™ 88.5%/Evolut™ R 11.5%.
Structural valve deterioration (SVD) was defined as an increase in mean gradient ≥ 10 mm Hg over five years with a mean gradient ≥ 20 mm Hg at last echo OR new onset/increase of central AR of ≥ moderate in severity.
CoreValve™, Evolut™ R, Evolut™ PRO, SAPIEN™*, SAPIEN 3, SAPIEN XT, and ACURATE neo™*.
Based on the longest available follow-up for each of the 10 studies used for this meta-analysis. SVD was defined by the respective authors of each paper.
Reardon MJ, et al. 5-Year Incidence, Timing and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials. Presented at ACC 2022. Updated data on file.
Ueyama H, Kuno T, Takagi H, et al. Meta-Analysis Comparing Valve Durability Among Different Transcatheter and Surgical Aortic Valve Bioprosthesis. Am J Cardiol. November 1, 2021;158:104-111.
Martinsson A, Nielsen SJ, Milojevic M, et al. Life Expectancy After Surgical Aortic Valve Replacement. J Am Coll Cardiol. November 30, 2021;78(22):2147-2157.